Home » viraloutbreaks
Category Archives: viraloutbreaks
Good news is here for around 500 million people of mostly developing countries who gets infected with the human whipworm, a potent physical and mental growth damager, now they can be hopeful for effective treatment in coming days as a new finding shows that the whipworm is killed at egg and adult stage by a new drug developed by the team from the three UK universities, Oxford, Manchester and University College London.
Currently there are no vaccines available for human whipworm and treatments are based on ages old drugs having low success rate. The team of researchers studies a class of dihydrobenzoxazepinonesm, which had never been related to regulating whipworms, found the compounds a more effective killer of the adult stages of whipworm than present drugs. Not only that, even whipworm eggs are also affected which are contagious and passed from infected faeces into healthy people by hand to mouth contact, quite often in areas where people live close together or areas with unsanitary toilets.
Generally, the whipworm eggs are highly resistant to UV radiation, extreme temperature changes and may remain viable for longer, however the newly studied compounds which are effective against the eggs could be used as a spray to stop whipworm infection at source itself.
Frederick A. Partridge, Emma A. Murphy, Nicky J. Willis, Carole J. R. Bataille, Ruth Forman, Narinder Heyer-Chauhan, Bruno Marinič, Daniel J. C. Sowood, Graham M. Wynne, Kathryn J. Else, Angela J. Russell, David B. Sattelle. Dihydrobenz[e][1,4] oxazepin-2(3H)-ones, a new anthelmintic chemotype immobilising whipworm and reducing infectivity in vivo. PLOS Neglected Tropical Diseases, 2017; 11 (2): e0005359 DOI: 10.1371/journal.pntd.0005359
A team of Scientists have recognized a protein that worn out the MERS virus, giving the hope for a potential relief to prevent and treat the incurable disease, according to a report published in Proceedings of the National Academy of Sciences on 27th July. Middle East Respiratory Syndrome (MERS) is an exceptionally lethal pulmonary infection instigated by a formerly unidentified coronavirus (CoV), possibly passed on to humans by infected camels. There is no licensed vaccine or antiviral available so far to treat MERS, which causes symptoms such as fever, cough and shortness of breath. The team isolated a potent MERS-CoV-neutralizing antibody, named LCA60, from memory B cells of an infected patient. LCA60 antibody binds to a novel site on the spike protein and effectively nullifies infection of MERS by meddling with the binding to the cellular receptor CD26. Scientists claim that LCA60 antibody can efficiently be used for prophylaxis, for postexposure prophylaxis of individuals at risk, or for the treatment of human cases of MERS infection. Notably, LCA60, when given to infected mice, dramatically reduced the amount of the MERS virus in the lungs within days. Even in the worst-case scenario, only one virus remained after three days for every 100 viruses at the start of the treatment. In most cases, the virus became untraceable within five days of treatment. The antibody fought the virus whether it was given a day before or a day after the mice were infected. Current MERS outbreak in China and South Korea has caused 186 infections and 36 deaths as of 28th July WHO report.
See in details;
D. Corti et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. PNAS. Published online July 27, 2015. doi: 10.1073/pnas.151019912